RJA
IMPL

Raymond James & Associates’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Raymond James & Associates’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-14,500
Closed -$6.24K – 3987
2023
Q3 		$6.24K Hold
14,500
– – ﹤0.01% 3773
2023
Q2 		$18.4K Hold
14,500
– – ﹤0.01% 3779
2023
Q1 		$20.3K Hold
14,500
– – ﹤0.01% 3800
2022
Q4 		$54.4K Buy
+14,500
New +$52.8K ﹤0.01% 3709

Other funds holding IMPL

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
DJSG
D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

Raymond James & Associates's IMPL Position: Q4 2023 in Review

Raymond James & Associates sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q4 2023, closing a stake of 14,500 shares — an estimated $6.24K sold.

Raymond James & Associates first reported a position in IMPL in Q4 2022 and held it in 4 quarters. The position peaked at $54.4K in Q4 2022. 2 funds tracked by Wall St. Rank hold IMPL as of Q4 2023.

  • Raymond James & Associates reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Raymond James & Associates sold 14,500 Impel Pharmaceuticals Inc. Common Stock shares in Q4 2023, an estimated $6.24K.
  • Raymond James & Associates first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q4 2022 and held it in 4 quarters.
  • Raymond James & Associates's Impel Pharmaceuticals Inc. Common Stock position peaked at $54.4K in Q4 2022.
  • 2 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q4 2023.

Based on Raymond James & Associates's 13F filing for Q4 2023, filed 16 Jan 2024.